Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $42 at Needham & Company, Analyst Maintains Buy Rating on Optimistic Tone on Company's Programs
Tweet Send to a Friend
Needham & Company analyst Serge Belanger lowered the price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV) to $42.00 (from $48.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
